Cvrx | Barostim

Cvrx | Barostim company information, Employees & Contact Information

Explore related pages

Related company profiles:

CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body’s own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/

Company Details

Employees
255
Founded
-
Address
Minneapolis, Mn 55445, Us
Phone
(763)416-2840
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
Website
cvrx.com
HQ
Minneapolis, MN
Looking for a particular Cvrx | Barostim employee's phone or email?

Cvrx | Barostim Questions

News

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 - Yahoo Finance

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 Yahoo Finance

CVRx, Inc. to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Quiver Quantitative

CVRx, Inc. to Announce Third Quarter 2025 Financial Results on November 5, 2025 Quiver Quantitative

CVRx (NASDAQ: CVRX) sets Nov. 5 results release; investor call at 4:30 p.m. ET - Stock Titan

CVRx (NASDAQ: CVRX) sets Nov. 5 results release; investor call at 4:30 p.m. ET Stock Titan

CVRx Reports Preliminary First Quarter 2025 Financial Results - GlobeNewswire

CVRx Reports Preliminary First Quarter 2025 Financial Results GlobeNewswire

CVRx Announces Positive News on Outpatient Payment for Barostim - Yahoo Finance

CVRx Announces Positive News on Outpatient Payment for Barostim Yahoo Finance

CVRx Secures Triple Medicare Payment Victory for Barostim: $45K Outpatient Coverage Confirmed - Stock Titan

CVRx Secures Triple Medicare Payment Victory for Barostim: $45K Outpatient Coverage Confirmed Stock Titan

CVRx, Inc. Announces Proposed CMS Payment for Barostim Implant Procedure Support - Quiver Quantitative

CVRx, Inc. Announces Proposed CMS Payment for Barostim Implant Procedure Support Quiver Quantitative

CVRx Reports Second Quarter 2025 Financial and Operating Results - Yahoo Finance

CVRx Reports Second Quarter 2025 Financial and Operating Results Yahoo Finance

CVRx Sets Q2 Earnings Date: Leading Cardiovascular Device Maker to Present Latest Financial Results - Stock Titan

CVRx Sets Q2 Earnings Date: Leading Cardiovascular Device Maker to Present Latest Financial Results Stock Titan

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim - Diagnostic and Interventional Cardiology

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim Diagnostic and Interventional Cardiology

AdvaMed Code of Ethics® - AdvaMed® - Advanced Medical Technology Association®

AdvaMed Code of Ethics® AdvaMed® - Advanced Medical Technology Association®

Cardiovascular Tech Leader CVRx Showcases Innovation at Major Growth Conference - Stock Titan

Cardiovascular Tech Leader CVRx Showcases Innovation at Major Growth Conference Stock Titan

Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure - Diagnostic and Interventional Cardiology

Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure Diagnostic and Interventional Cardiology

CVRx Posts Mixed Q1 Earnings: 15% Growth Meets Headwinds as Expansion Continues - Stock Titan

CVRx Posts Mixed Q1 Earnings: 15% Growth Meets Headwinds as Expansion Continues Stock Titan

CVRx Receives MR-conditional Labeling Approval for its Barostim Heart Failure System - Diagnostic and Interventional Cardiology

CVRx Receives MR-conditional Labeling Approval for its Barostim Heart Failure System Diagnostic and Interventional Cardiology

Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure - Diagnostic and Interventional Cardiology

Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure Diagnostic and Interventional Cardiology

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering - GlobeNewswire

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering GlobeNewswire

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts - GlobeNewswire

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts GlobeNewswire

CVRx announces Medicare win for Barostim therapy - MassDevice

CVRx announces Medicare win for Barostim therapy MassDevice

Fear And Fundamentals: Why CVRx Stock’s Sell-Off Ignores Its True Potential (NASDAQ:CVRX) - Seeking Alpha

Fear And Fundamentals: Why CVRx Stock’s Sell-Off Ignores Its True Potential (NASDAQ:CVRX) Seeking Alpha

CVRx, Inc.: Overreaction Creates Buying Opportunity - Seeking Alpha

CVRx, Inc.: Overreaction Creates Buying Opportunity Seeking Alpha

A second breath: How doctors with McLeod Health combat congestive heart failure through Barostim therapy - The Item

A second breath: How doctors with McLeod Health combat congestive heart failure through Barostim therapy The Item

A no-brainer: CVRx plots $92M IPO for its neurostim implant for heart failure - Fierce Biotech

A no-brainer: CVRx plots $92M IPO for its neurostim implant for heart failure Fierce Biotech

Algorithm can help optimize device therapy for patients with HFrEF - Healio

Algorithm can help optimize device therapy for patients with HFrEF Healio

CVRx Barostim Therapy Clinical Trial Results Presented at ESC-Heart Failure Conference - Diagnostic and Interventional Cardiology

CVRx Barostim Therapy Clinical Trial Results Presented at ESC-Heart Failure Conference Diagnostic and Interventional Cardiology

CVRX Stock Price and Chart — NASDAQ:CVRX - TradingView

CVRX Stock Price and Chart — NASDAQ:CVRX TradingView

Neuromodulation Device Approved for Patients With Advanced Heart Failure - Medical Professionals Reference

Neuromodulation Device Approved for Patients With Advanced Heart Failure Medical Professionals Reference

CVRx is going the IPO route - MassDevice

CVRx is going the IPO route MassDevice

FDA Approves Pacemaker-like Device to Treat Heart Failure - Diagnostic and Interventional Cardiology

FDA Approves Pacemaker-like Device to Treat Heart Failure Diagnostic and Interventional Cardiology

Barostim Therapy Projected to be Cost-Effective in Treating Resistant Hypertension - Diagnostic and Interventional Cardiology

Barostim Therapy Projected to be Cost-Effective in Treating Resistant Hypertension Diagnostic and Interventional Cardiology

First Implant Made for Barostim neo Device to Treat Hypertension - Diagnostic and Interventional Cardiology

First Implant Made for Barostim neo Device to Treat Hypertension Diagnostic and Interventional Cardiology

Electronic cuff in neck could keep blood pressure in check - New Atlas

Electronic cuff in neck could keep blood pressure in check New Atlas

Top Cvrx | Barostim Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant